Rethinking Multiple Sclerosis: Why Everything We Thought We Knew Is Changing
- Share via
Key Facts
- MS involves both inflammation and neurodegeneration from the outset, not just one after the other.
- B-cells, a type of immune cell, are now understood to be critical drivers of the disease, a major shift from the previous T-cell-only focus.
- In the U.S., Black individuals have the highest incidence of multiple sclerosis, highlighting profound health disparities linked to structural factors.
- High-efficacy therapies that target B-cells have fundamentally changed treatment strategies and patient outcomes.
- Diagnosis relies on the internationally recognized McDonald criteria, which use MRI to show evidence of damage spread across different areas of the nervous system and over time.
The story we used to tell about multiple sclerosis was simple. Clean. Maybe a little too clean. We taught it in lecture halls and explained it to patients. The script was always the same: MS is an autoimmune disease where the body’s T-cells—the special forces of the immune system—go rogue. They mistake the nervous system for an invader and attack the myelin sheath, the fatty insulation that keeps our nerve signals moving fast. Strip away that insulation, you get short circuits. Relapses. Disability. It was a neat narrative. T-cells were the clear villain.
But the real world is messy. And the clues that our story was wrong came from our own treatments. New therapies came along that absolutely hammered B-cells—another part of the immune army we’d mostly ignored in the MS story. And they worked. Frighteningly well [4]. That begged a huge question. If this was a T-cell war, why was taking out the B-cell infantry so brutally effective?
It forced a complete reset. Turns out, B-cells aren’t just standing around. They’re key players, maybe even the ringleaders that get the T-cells riled up and keep the fires of chronic inflammation burning [1] [2]. This wasn’t some minor academic correction. It changed everything. It meant our entire working model of the disease was incomplete. We’d been staring at one piece of the puzzle, thinking it was the whole picture. The neat story was wrong.
This disease is a product of a murky conspiracy between a person’s genes and some environmental trigger we still can’t nail down [3] [10]. A virus from childhood? A chronic deficiency? We have a list of suspects, but no convictions. What we do know is that once it kicks off, it’s a cascade of damage. And it’s not just about the myelin anymore. It’s about the nerve itself. The wire, not just the insulation.
First job is getting the diagnosis right. For that, we have the MRI. It’s our window into the damage [9]. We hunt for lesions—the scars of past attacks—in the brain and spinal cord. But one picture isn’t enough. To be sure it’s MS, we have to prove the damage is happening in different places and at different times. Dissemination in space and time. That’s the mantra.
The McDonald criteria are the rules of the game for this, and they’ve been sharpened over the years to be faster and more accurate [13]. The 2017 update, for example, cut down the waiting time for a diagnosis. Good. Because time is brain. The sooner we know, the sooner we can act. We even have advanced imaging now that lets us see past the obvious lesions to the subtle, fraying wires underneath it all [15].
But the sharper picture from our MRIs showed us something else. Something uncomfortable. The old textbooks taught us MS was a disease of white people with Northern European roots. That was the classic patient profile. Another part of our simple story. And another part that was dead wrong [8].
The data coming out now paints a very different picture. In the United States, Black individuals don’t just get MS—they have the highest incidence of the disease [14]. Hispanic communities are also hit hard. This isn’t a footnote. It’s the headline. It tells us that MS risk is shaped by more than just ancestry. It’s shaped by society. It’s about where you live, your access to care, and the systemic biases baked into the world [14]. It’s a humbling reality check. A disease doesn’t happen in a biological vacuum. It happens in the real world [7].
The last two decades? An absolute explosion in treatments [2] [5]. We went from having almost nothing to a whole arsenal of drugs. The new high-efficacy therapies, especially those B-cell killers, can slam the brakes on relapses and new MRI lesions [4]. They are powerful weapons against the inflammatory part of MS.
But stopping the inflammation, we’re learning, is only half the job. MS isn’t one thing. It’s two. A two-headed monster. It is an inflammatory disease, yes. But it is also a neurodegenerative one [2] [6]. From day one, nerve fibers are being quietly damaged and permanently lost. Axonal transection. That’s the technical term. It means the nerve fiber is cut. It doesn’t grow back. This is the stealthy process that drives progressive disability, the slow worsening that can happen even when a person feels fine.
For years, we saw this as a two-act play: an early, inflammatory stage, followed by a later, degenerative stage. Another simple story. Also wrong. We now know they are partners in crime. Inflammation and neurodegeneration are happening at the same time, a vicious cycle running from day one [12].
This changes the mission entirely. The new mandate isn’t just to cool down the immune system. It’s to protect the brain itself. Neuroprotection. That’s the holy grail now [11] [12]. We need drugs that not only stop the attacks but also shield the neurons from the fallout and, maybe, help the brain heal itself. We aren’t there yet. But that’s where everything is headed. The goalpost moves. It’s not just “no new attacks” anymore. It’s “save the brain.” Preserve function for the long haul. It means we have to finally toss out the simple stories and face the complicated, challenging reality of what this disease truly is.
References
[1] Yamout, B. I., & Alroughani, R. (2018). Multiple Sclerosis. Seminars in neurology, 38(2), 212–225. https://doi.org/10.1055/s-0038-1649502
[2] Hauser, S. L., & Cree, B. A. C. (2020). Treatment of Multiple Sclerosis: A Review. The American journal of medicine, 133(12), 1380–1390.e2. https://doi.org/10.1016/j.amjmed.2020.05.049
[3] Ghasemi, N., Razavi, S., & Nikzad, E. (2017). Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell journal, 19(1), 1–10. https://doi.org/10.22074/cellj.2016.4867
[4] Galota, F., Marcheselli, S., De Biasi, S., Gibellini, L., Vitetta, F., Fiore, A., Smolik, K., De Napoli, G., Cardi, M., Cossarizza, A., & Ferraro, D. (2025). Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells. Cells, 14(8), 606. https://doi.org/10.3390/cells14080606
[5] Martin, R., Sospedra, M., Rosito, M., & Engelhardt, B. (2016). Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis. European journal of immunology, 46(9), 2078–2090. https://doi.org/10.1002/eji.201646485
[6] McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021). Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA, 325(8), 765–779. https://doi.org/10.1001/jama.2020.26858
[7] Kapica-Topczewska, K., Kulakowska, A., Kochanowicz, J., & Brola, W. (2025). Epidemiology of multiple sclerosis: global trends, regional differences, and clinical implications. Neurologia i neurochirurgia polska, 10.5603/pjnns.103955. Advance online publication. https://doi.org/10.5603/pjnns.103955
[8] Dobson, R., & Giovannoni, G. (2019). Multiple sclerosis - a review. European journal of neurology, 26(1), 27–40. https://doi.org/10.1111/ene.13819
[9] Elahi, R., Taremi, S., Najafi, A., Karimi, H., Asadollahzadeh, E., Sajedi, S. A., Rad, H. S., & Sahraian, M. A. (2025). Advanced MRI Methods for Diagnosis and Monitoring of Multiple Sclerosis (MS). Journal of magnetic resonance imaging : JMRI, 10.1002/jmri.29817. Advance online publication. https://doi.org/10.1002/jmri.29817
[10] Jakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024). Multiple sclerosis. Lancet (London, England), 403(10422), 183–202. https://doi.org/10.1016/S0140-6736(23)01473-3
[11] Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018). Multiple sclerosis. Lancet (London, England), 391(10130), 1622–1636. https://doi.org/10.1016/S0140-6736(18)30481-1
[12] Coclitu, C. I., Constantinescu, C. S., & Tanasescu, R. (2025). Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms. Expert review of neurotherapeutics, 25(7), 791–817. https://doi.org/10.1080/14737175.2025.2510405
[13] Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., Fujihara, K., Galetta, S. L., Hartung, H. P., Kappos, L., Lublin, F. D., Marrie, R. A., Miller, A. E., Miller, D. H., Montalban, X., Mowry, E. M., … Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet. Neurology, 17(2), 162–173. https://doi.org/10.1016/S1474-4422(17)30470-2
[14] Langer-Gould, A. M., Cepon-Robins, T. J., Benn Torres, J., Yeh, E. A., & Gildner, T. E. (2025). Embodiment of structural racism and multiple sclerosis risk and outcomes in the USA. Nature reviews. Neurology, 21(7), 370–382. https://doi.org/10.1038/s41582-025-01096-5
[15] Sbardella, E., Tona, F., Petsas, N., & Pantano, P. (2013). DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications. Multiple sclerosis international, 2013, 671730. https://doi.org/10.1155/2013/671730
